Kyverna Therapeutics

Kyverna is a patient-centered, clinical-stage biopharmaceutical company based in the United States, with approximately 51 employees. The company is focused on developing cell therapies for patients suffering from autoimmune diseases, such as lupus nephritis, systemic sclerosis, multiple sclerosis, and myasthenia gravis, using its innovative chimeric antigen receptor (CAR) T-cell therapy platform.